Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cancer Research Technology Ltd.: Biopharma's Gateway to Cancer-Focused Academic Research

This article was originally published in Start Up

Executive Summary

Cancer Research Technology - the technology transfer arm of Cancer Research UK, the world's largest charity - has long moved beyond simply commercializing and managing the IP generated by the half billion in research funding provided by Cancer Research UK to five core research institutes across the UK, as well as to researchers at dozens of other universities and organizations. CRT has a growing, 85-strong in-house drug discovery capability which is being expanded with the help of a five-year, £7 million ($11 million) grant from Cancer Research UK - and it's this that lured in AstraZeneca and another industry collaborator, Cephalon.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts